On March 20, 2024, RetinalGenix Technologies Inc. closed the transaction. The transaction included participation from 25 investors. The company paid $3,500,000 as sales commissions in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4859 USD | +2.06% |
|
-0.84% | -44.00% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.00% | 17.9M | |
+18.09% | 44.48B | |
+44.19% | 40.57B | |
-8.38% | 38.82B | |
+34.66% | 32.22B | |
-8.34% | 27.84B | |
+16.10% | 26.79B | |
+49.73% | 14.31B | |
+36.71% | 12.7B | |
-6.60% | 11.23B |
- Stock Market
- Equities
- UNCY Stock
- News Unicycive Therapeutics, Inc.
- Unicycive Therapeutics, Inc. announced that it has received $50 million in funding